home / stock / capr / capr news

CAPR News and Press, Capricor Therapeutics Inc. From 09/24/19

Stock Information
Company Name: Capricor Therapeutics Inc.
Stock Symbol: CAPR
Market: NASDAQ
Website: capricor.com
Menu
CAPR CAPR Quote CAPR Short CAPR News CAPR Articles CAPR Message Board
Get CAPR Alerts

News, Short Squeeze, Breakout and More Instantly...
CAPR - Capricor Therapeutics to Meet with FDA to Discuss CAP-1002 to Treat Duchenne Muscular Dystrophy

LOS ANGELES, Sept. 24, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy (DMD) and other rare disorders, announced to...
CAPR - SBGL, LXRX among top premarket gainers

Aclaris Therapeutics (NASDAQ: ACRS ) +73%  on positive A-101 data . More news on: Aclaris Therapeutics, Inc., Capricor Therapeutics, Inc., Ocean Power Technologies, Inc., Stocks on the move, Read more ...

CAPR - Capricor Therapeutics to Present Results from the HOPE-2 Trial of CAP-1002 in Duchenne Muscular Dystrophy in a Late Breaking Session of the World Muscle Society

LOS ANGELES, Sept. 17, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy (DMD) and other rare disorders, today announ...

CAPR - Capricor Therapeutics (CAPR) Presents At 21st Annual H.C. Wainwright Global Investment Conference - Slideshow

The following slide deck was published by Capricor Therapeutics, Inc. in conjunction with this Read more ...

CAPR - Capricor Therapeutics to Present at Upcoming Conferences

LOS ANGELES, Sept. 06, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR),  a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy and other rare disorders, today announce...

CAPR - Capricor Therapeutics' (CAPR) CEO Linda Marbán on Q2 2019 Results - Earnings Call Transcript

Capricor Therapeutics, Inc. (CAPR) Q2 2019 Earnings Conference Call August 6, 2019 4:30 PM ET Company Participants Linda Marbán – Chief Executive Officer AJ Bergmann – Chief Financial Officer Conference Call Participants Adheip Mally – Maxim Group ...

CAPR - Capricor Therapeutics EPS beats by $0.21, beats on revenue

Capricor Therapeutics (NASDAQ: CAPR ): Q2 GAAP EPS of -$0.59 beats by $0.21 . More news on: Capricor Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

CAPR - Capricor Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update

Positive Results from HOPE-2 Interim Analysis Reported in July To Host Conference Call and Webcast Today at 4:30 p.m. ET LOS ANGELES, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first...

CAPR - Capricor Therapeutics to Present Second Quarter 2019 Financial Results and Recent Corporate Update on August 6

LOS ANGELES, July 30, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy and other rare disorders, will report its secon...

CAPR - Earnings dominate premarket gainers

EDAP TMS S.A. (NASDAQ: EDAP ) +20%  on preliminary Q2 revenue growth . More news on: EDAP TMS S.A., Diebold Nixdorf, Incorporated, Capricor Therapeutics, Inc., Stocks on the move, Read more ...

Previous 10 Next 10